Compare Moderna, Inc. (MRNA) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ProShares Ultra Gold ETF — how do they compare? Moderna, Inc. trades at $218.85 (market cap $78.65B), while ProShares Ultra Gold ETF trades at $46.27 (market cap $716.59M). The key difference: Moderna, Inc. is far larger — about 109.8× ProShares Ultra Gold ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and ProShares Ultra Gold ETF for 23 Days on average.
| MRNA | UGL | |
|---|---|---|
Market Cap | $78.65B | $716.59M |
Volume | 37,373,437 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $203.46 | $85.62 |
52-Week Low | $22.36 | $42.79 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
UGL trades at $46.24, up 4.07% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $46 and support at $45. Financial ratios are unavailable, limiting fundamental assessment. Recent gold-related news highlights volatility from Treasury yields and Fed policy, influencing sentiment.
Outlook remains cautious due to bearish technicals and macroeconomic pressures. Risks include interest rate sensitivity and lack of financial transparency. Investors should await earnings reports for fundamental clarity amid current market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
